Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 May 6;15:72. doi: 10.1186/1471-2369-15-72

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2014 Waldek and Feriozzi; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Change in eGFR in patients with Fabry disease and CKD during treatment with agalsidase alfa. Republished with permission of Elsevier, from [Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data. Mehta A et al. Lancet 374: 2009]; permission conveyed through Copyright Clearance Centre, Inc. [68]. Data are plotted according to baseline stage of CKD. Patient numbers are shown in parentheses. Data from previous studies for the expected natural fall in renal function in patients with Fabry disease and the effects of agalsidase beta are plotted for reference and comparison. *[69]; †[70]; ‡[18]; §[41]; ¶[63]; ||[26]. CKD, chronic kidney disease; GFR, glomerular filtration rate.